Items where authors include "Hunter, H."

Article

Debelle, H., Packer, E., Beales, E. et al. (13 more authors) (2023) Feasibility and usability of a digital health technology system to monitor mobility and assess medication adherence in mild-to-moderate Parkinson's disease. Frontiers in Neurology, 14. 1111260. ISSN 1664-2295

Duque-Afonso, J., Finke, J., Labopin, M. et al. (18 more authors) (2022) Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 57 (8). pp. 1269-1276. ISSN 0268-3369

Metwally, M., Chatters, R., Pye, C. et al. (16 more authors) (2022) Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation : RCT and systematic review. Health Technology Assessment, 26 (10). pp. 1-211.

Dignan, F.L., Hamblin, A., Chong, A. et al. (6 more authors) (2021) Survivorship care for allogeneic transplant patients in the UK NHS : changes centre practice, impact of health service policy and JACIE accreditation over 5 years. Bone Marrow Transplantation, 56 (3). pp. 673-678. ISSN 0268-3369

Ahmedzai, S.H., Snowden, J.A. orcid.org/0000-0001-6819-3476, Ashcroft, A.J. et al. (19 more authors) (2019) Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Galleu, A., Milojkovic, D., Deplano, S. et al. (21 more authors) (2019) Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. British Journal of Haematology, 185 (1). pp. 89-92. ISSN 0007-1048

Cook, G., Ashcroft, A.J., Cairns, D.A. et al. (17 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol, 3 (7). e340-e351.

Parrish, C., Morris, C.T.C.M., Williams, C.D. et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791